GLP-1 Agonists Guide
How GLP-1 receptor agonists work, how they compare, and how to build a protocol that fits your goals
Ask FoxAIPeptide research chat, grounded in peer-reviewed papers.What Are GLP-1 Agonists?
GLP-1 (glucagon-like peptide-1) agonists are a class of medications that mimic a natural gut hormone released after eating. They work through multiple mechanisms: slowing stomach emptying so you feel full longer, reducing appetite signals in the brain, and improving how your body handles blood sugar.
These medications are the most effective pharmaceutical option for weight loss available today — clinical trials show sustained loss of 15-24% of body weight over 12-18 months, a range no prior drug class has matched. The three main compounds differ in which hormone receptors they activate: semaglutide targets GLP-1 only (appetite), tirzepatide adds GIP (direct fat cell engagement), and retatrutide adds glucagon (liver fat mobilization) on top of stronger GIP. Each additional receptor changes not just how much weight you lose, but where it comes from and how your body composition shifts. The class was originally developed for type 2 diabetes; the obesity indication followed once the weight-loss signal became impossible to ignore.
GLP-1 Compounds at a Glance
| Compound | Brand Names | Mechanism | Avg. Weight Loss | Status |
|---|---|---|---|---|
| Semaglutide | Ozempic, Wegovy | GLP-1 Receptor Activation | 12–15% | 🟢 FDA Approved |
| Tirzepatide | Mounjaro, Zepbound | Dual GIP/GLP-1 Receptor Activation | 18–21% | 🟢 FDA Approved |
| Retatrutide | Investigational (Phase 3) | Triple Agonist: GLP-1 / GIP / Glucagon | 22–24% | 🟡 Phase 3 Ongoing |
Which one is right for me? Semaglutide is the conservative starter — longest track record, oral option, and the strongest cardiovascular outcomes data of the class (SELECT trial, 20% MACE reduction). Tirzepatide is the stronger weight-loss tool in non-diabetic obesity and produces a better fat-to-lean ratio thanks to GIP. Retatrutide is investigational but has the highest ceiling, especially for liver fat and visceral fat — worth the monitoring burden only when those compartments are the actual target.
GLP-1 Tools & Guides
Compare Compounds
Tirzepatide hits GIP and GLP-1. Retatrutide adds glucagon. That is not cosmetic — it changes body composition, liver-fat response, and the side-effect profile. Compare at equivalent doses.
CompareDose Frequency & Titration Optimizer
Splitting a weekly dose into two injections flattens the peak-trough swing that drives most side effects. Visualize the plasma curve at weekly vs twice-weekly and see where the nausea lives.
CalculateBuild Protocol
Five steps: pick your compound, set frequency, add support stack, calculate first dose, ship protocol. For when you want the decisions written down, not just scrolled past.
StartManaging GLP-1 Fatigue
Why semaglutide, tirzepatide, and retatrutide cause fatigue — and what actually fixes each type.
Read guideSupport Stacks for GLP-1s
How to preserve lean mass during GLP-1 therapy with targeted peptide and nutrition support.
Read guideRetatrutide: Advanced Stack
Dual-axis protocol to protect lean mass while maximizing fat loss on retatrutide.
Read guideAll GLP-1 Content
Deep dives, practical protocols, and clinical guidance across all GLP-1 topics.
Browse allFrequently Asked Questions
What are GLP-1 agonists and how do they work?
GLP-1 (glucagon-like peptide-1) agonists mimic a gut hormone that regulates appetite and blood sugar. They slow the stomach so food takes longer to clear (gastric emptying), which extends fullness between meals. They reduce appetite signals in the brain, so the drive to eat drops. And they improve how your cells respond to blood sugar (insulin sensitivity). The combined effect is lower calorie intake, which drives weight loss of 15-25% of body weight in clinical trials.
What is the difference between semaglutide, tirzepatide, and retatrutide?
Semaglutide (Ozempic/Wegovy) is a pure GLP-1 agonist — it suppresses appetite but cannot directly signal fat cells (GLP-1 receptors aren't expressed in adipose tissue), producing ~15% weight loss and a 60:40 fat-to-lean ratio. Its key advantages sit in second-organ endpoints — SELECT showed a 20% cardiovascular event reduction in obesity with established heart disease, and ESSENCE showed 62.9% MASH resolution vs 34.1% on placebo in biopsy-confirmed liver disease. Tirzepatide (Mounjaro/Zepbound) adds GIP receptor agonism, which directly engages fat cells via thermogenesis — producing 20-22% weight loss and a better 75:25 fat-to-lean ratio in non-diabetic obesity. Retatrutide is a triple agonist with redesigned receptor potencies (8.9× GIP, 0.4× GLP-1, 0.3× glucagon) — the glucagon component directly mobilizes liver fat (84% reduction in Phase 2), and the stronger GIP was engineered to push through impaired GIP signaling in type 2 diabetes. Phase 3 TRIUMPH-4 (Lilly topline Dec 11, 2025) delivered up to 71.2 lb average weight loss — 28.7% at 12 mg over 68 weeks; FDA approval anticipated 2027.
Which GLP-1 medication causes the most weight loss?
Retatrutide now leads with up to 71.2 lb average weight loss — 28.7% at 12 mg over 68 weeks — per the Phase 3 TRIUMPH-4 topline (Lilly press release, Dec 11, 2025). Tirzepatide followed at 22.5% over 72 weeks (SURMOUNT-1); semaglutide at 14.9% over 68 weeks (STEP-1). In the head-to-head SURMOUNT-5 trial, tirzepatide produced 47% more weight loss than semaglutide (20.2% vs 13.7%). TRIUMPH-4 enrolled adults with obesity plus knee osteoarthritis, not general obesity — Phase 3 readouts for general-obesity populations run through 2026. Retatrutide is not yet FDA-approved (anticipated 2027); semaglutide and tirzepatide are.
How long does it take to see results from GLP-1 medications?
Most people notice reduced appetite within the first week. Weight loss typically begins in weeks 2-4. By week 8-12, users commonly see 5-10% weight loss. Maximum effects usually occur at 16-20 weeks on maintenance dose, with continued gradual loss through 68-72 weeks.
What are common side effects of GLP-1 agonists?
GI effects dominate the adjustment phase: nausea (20-40%), vomiting, diarrhea, and constipation — most resolve within 2-4 weeks of each titration step, and slow escalation reduces severity. Beyond GI, four signals are clinically material and well-documented: gastroparesis (Sodhi 2023, adjusted HR 3.7 — the FDA added ileus to the label in September 2023), biliary disease (He 2022 76-RCT meta-analysis, RR 1.37 any biliary event, highest with semaglutide), NAION or non-arteritic ischemic optic neuropathy (Hathaway 2024 flagged the signal; now on the label as a warning), and lean mass loss (STEP-1 DXA substudy showed ~40% of weight lost on semaglutide was lean tissue — tirzepatide trends closer to 25% thanks to GIP). For the full lean-mass breakdown see GLP-1 Muscle Preservation.
Can I take GLP-1 medications if I have type 2 diabetes?
Yes — GLP-1 agonists were originally developed for type 2 diabetes. Semaglutide (Ozempic) and tirzepatide (Mounjaro) are FDA-approved for diabetes management, improving HbA1c by 1.5-2.3%. However, weight loss results differ between diabetic and non-diabetic populations. In T2D, GIP signaling is impaired (the "incretin defect"), which blunts tirzepatide's body-composition advantage — head-to-head data shows similar fat-to-lean ratios for tirzepatide and semaglutide in diabetic patients. Retatrutide was specifically designed with stronger GIP (8.9× native) and added glucagon to partially overcome this limitation.
How do I prevent muscle loss while taking GLP-1 medications?
Resistance training 2-4x weekly and high protein intake (1.6-2.2g per kg body weight) are essential. Without exercise, lean mass losses vary by drug: semaglutide shows a 60:40 fat-to-lean ratio (40% of weight lost is lean mass), while tirzepatide achieves 75:25 in non-diabetic populations thanks to GIP receptor activation in fat cells. This body-composition advantage narrows in type 2 diabetes where GIP is impaired. Regardless of drug, training and protein are the biggest levers for preserving muscle.
Medical Disclaimer
The content in this GLP-1 guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.